NCT02551809View on ClinicalTrials.gov

Evaluate the Safety, Tolerability, Immunogenicity and Efficacy of UB-311 in Mild Alzheimer's Disease (AD) Patients

PHASE2CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

October 31, 2015

Primary Completion Date

August 31, 2018

Study Completion Date

August 31, 2018

Conditions

Alzheimer's Disease

Interventions

BIOLOGICAL

UB-311

Intramuscular injection

DRUG

Placebo

Intramuscular injection

Trial Locations (4)

Unknown

Kaohsiung Chang Gung Memorial Hospital (KS-CGMH), Kaohsiung City

National Taiwan University Hospital (NTUH), Taipei

Taipei Veterans General Hospital (TVGH), Taipei

Linkou Chang Gung Memorial Hospital (LK-CGMH), Taoyuan District

All Listed Sponsors

lead

United Neuroscience Ltd.

INDUSTRY

NCT02551809 - Evaluate the Safety, Tolerability, Immunogenicity and Efficacy of UB-311 in Mild Alzheimer's Disease (AD) Patients | Biotech Hunter | Biotech Hunter